STOCK TITAN

Edwards Lifesciences (EW) VP sells 22,680 shares after option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp corporate VP Donald E. Bobo Jr. exercised employee stock options for 22,680 shares of common stock at an exercise price of $59.2567 per share. On the same date, he sold a total of 22,680 shares in open-market transactions at weighted average prices of $80.5915 and $80.0494 per share.

After these transactions, he directly holds 21,266.2532 shares of common stock, with additional indirect holdings of shares represented in a 401(k) plan and a trust. The filing states that these trades were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.

Positive

  • None.

Negative

  • None.
Insider BOBO DONALD E JR
Role CVP,Strategy/Corp Development
Sold 22,680 shs ($1.82M)
Type Security Shares Price Value
Exercise Employee Stock Option (Right to Acquire) 22,680 $0.00 --
Exercise Common Stock 22,680 $59.2567 $1.34M
Sale Common Stock 4,676 $80.5915 $377K
Sale Common Stock 18,004 $80.0494 $1.44M
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Employee Stock Option (Right to Acquire) — 0 shares (Direct); Common Stock — 43,946.253 shares (Direct); Common Stock — 38,934.629 shares (Indirect, 401(k))
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.
Options exercised 22,680 shares Employee stock options exercised on April 2, 2026
Exercise price $59.2567 per share Strike price for employee stock option exercise
Shares sold (block 1) 4,676 shares at $80.5915 Open-market sale of common stock on April 2, 2026
Shares sold (block 2) 18,004 shares at $80.0494 Second open-market sale block on April 2, 2026
Direct holdings after 21,266.2532 shares Direct common stock owned after reported transactions
401(k) holdings 38,934.6294 shares Shares represented in issuer’s 401(k) plan statement
Trust holdings 121,756 shares Indirect ownership by trust reported in the filing
10b5-1 plan adoption date February 27, 2025 Date the Rule 10b5-1 trading plan was adopted
Employee Stock Option (Right to Acquire) financial
"security_title: "Employee Stock Option (Right to Acquire)""
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" for common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
401(k) Plan financial
"shares represented on the most recent statement of the Issuer's 401(k) Plan"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOBO DONALD E JR

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CVP,Strategy/Corp Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/02/2026M(1)22,680A$59.256743,946.2532D
Common Stock04/02/2026S(1)4,676D$80.5915(2)39,270.2532D
Common Stock04/02/2026S(1)18,004D$80.0494(3)21,266.2532D
Common Stock38,934.6294(4)I401(k)
Common Stock121,756IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Acquire)$59.256704/02/2026M22,68006/08/201905/07/2026Common Stock22,680$0.00000.0000D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
2. This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
4. Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edwards Lifesciences (EW) executive Donald E. Bobo Jr. report on this Form 4?

He reported exercising employee stock options for 22,680 Edwards Lifesciences shares and selling 22,680 common shares in open-market trades. The activity reflects an exercise-and-sell pattern rather than a new open-market purchase of stock.

How many Edwards Lifesciences (EW) options did Donald E. Bobo Jr. exercise and at what price?

He exercised employee stock options covering 22,680 Edwards Lifesciences shares at an exercise price of $59.2567 per share. These options were originally granted earlier and were exercised before their stated expiration date in 2026.

At what prices did Donald E. Bobo Jr. sell Edwards Lifesciences (EW) shares?

He sold 22,680 Edwards Lifesciences common shares in multiple trades with weighted average prices of $80.5915 and $80.0494 per share. Detailed trade-by-trade prices are available upon request as noted in the filing footnotes.

How many Edwards Lifesciences (EW) shares does Donald E. Bobo Jr. hold after these transactions?

Following the reported transactions, he directly owns 21,266.2532 Edwards Lifesciences common shares. The Form 4 also shows additional indirect holdings through a 401(k) plan and a trust, which increase his overall beneficial exposure.

Were Donald E. Bobo Jr.’s Edwards Lifesciences (EW) trades made under a Rule 10b5-1 plan?

Yes. The filing states all reported transactions were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025. Such plans pre-schedule trades, making their timing more routine and less discretionary.

Does this Edwards Lifesciences (EW) Form 4 show any remaining stock options after the exercise?

The Form 4 reports the exercise of 22,680 employee stock options and shows no remaining derivative positions in the derivative summary. This indicates those specific options were fully exercised in the reported transaction.